You are here

  • Home
  • Archive
  • Volume 82, Issue 8
  • Response to: Correspondence on “New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE” by Pons-Estel et al

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: Correspondence on “New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE” by Pons-Estel et al
  1. Laura Whittall-Garcia1,
  2. Dafna D Gladman1,
  3. Murray Urowitz1,
  4. Jiandong Su2,
  5. Zahi Touma1,
  6. Sindhu R Johnson1,3
  1. 1 Division of Rheumatology, Department of Medicine, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
  2. 2 Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto, Ontario, Canada
  3. 3 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
  1. Correspondence to Dr Sindhu R Johnson, Division of Rheumatology, Department of Medicine, Toronto Western Hospital, Mount Sinai Hospital; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Sindhu.Johnson{at}uhn.ca

http://dx.doi.org/10.1136/annrheumdis-2021-221014

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Dr Pons-Estel and colleagues1 for their interest in our2 paper proposing that a score of 20 or more in the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria3 4 predicts more severe disease activity in the following 5 years after the systemic lupus erythematosus (SLE) classification.2

    Pons-Estel et al 1 demonstrated that 98 (15.31%) patients who were classified by 1982/1997 ACR criteria, but not classified as SLE with the 2019 EULAR/ACR classification criteria, having a score of less than 10 points, accrued less damage compared with those who had a score of ≥10.5 In our cohort of patients with SLE, only …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors All authors contributed to study design, data collection and/or evaluation and critical review of the final manuscript.

    • Funding Support for this study came from the Lupus Programme, Centre for Prognosis Studies in the Rheumatic Diseases. SRJ is supported by a Canadian Institutes of Health Research Award. ZT is supported by a research salary award from the Department of Medicine, University of Toronto.

    • Competing interests SRJ reports grants from Bayer, Boehringer Ingelheim, Corbus, GSK, Roche and Merck, and personal fees from Boehringer Ingelheim and Ikaria.

    • Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles